Bradley Canino
Stock Analyst at Guggenheim
(1.99)
# 3,086
Out of 4,974 analysts
86
Total ratings
32%
Success rate
-2.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $34 | $17.04 | +99.53% | 6 | Sep 4, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.94 | +410.20% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.22 | +22.95% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $6.99 | +171.82% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $4.12 | +458.25% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $7.83 | +551.34% | 6 | Feb 12, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $70 → $115 | $24.06 | +377.97% | 2 | Dec 3, 2024 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $8.22 | +131.14% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $55.69 | -24.58% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $25.98 | +53.96% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $80.89 | +66.89% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $10.88 | +83.82% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.91 | +423.56% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.75 | +471.43% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $67.47 | +46.73% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.72 | +414.71% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $43.50 | +26.44% | 4 | Feb 23, 2024 |
Syndax Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $34
Current: $17.04
Upside: +99.53%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.94
Upside: +410.20%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.22
Upside: +22.95%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $6.99
Upside: +171.82%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $4.12
Upside: +458.25%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $7.83
Upside: +551.34%
Janux Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $70 → $115
Current: $24.06
Upside: +377.97%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $8.22
Upside: +131.14%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $55.69
Upside: -24.58%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $25.98
Upside: +53.96%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $80.89
Upside: +66.89%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $10.88
Upside: +83.82%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.91
Upside: +423.56%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.75
Upside: +471.43%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $67.47
Upside: +46.73%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.72
Upside: +414.71%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $43.50
Upside: +26.44%